Microcap Ledger Harvard Bioscience Inc $HBIO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Laboratory Analytical Instruments
- Headquarters
- Holliston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 4,552,305 [10-Q 2026-08-11]
What the company doesAI summary of filing
Harvard Bioscience develops, manufactures, and sells technologies, products, and services for life science applications including research, drug and therapy discovery, bioproduction, and preclinical testing. The company sells to academic institutions, government laboratories, pharmaceutical companies, biotechnology companies, and contract research organizations through direct sales and distribution channels globally. The company generates revenue from hardware, software, consumables, and services, with product prices typically ranging from $1,000 to over $100,000. Harvard Bioscience is a revenue-generating company with operations in the United States, Europe, and China. [10-K 2026-03-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $43.48M | −$6.33M | −$337.0K | $6.50M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | $86.55M | −$56.70M | $6.73M | $8.61M | [10-K 2026-03-13] |
| FY ended Dec 2024 | $94.14M | −$12.40M | $1.44M | $4.11M | [10-K 2026-03-13] |
- Quarterly cash burn
- −$168.5K
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 43,616,621 | [10-Q 2024-11-08] |
| 2025-03-05 | 44,074,475 | [10-K 2025-03-14] |
| 2025-05-05 | 44,213,746 | [10-Q 2025-05-12] |
| 2025-08-04 | 44,531,198 | [10-Q 2025-08-11] |
| 2025-11-03 | 44,579,665 | [10-Q 2025-11-06] |
| 2026-03-05 | 44,719,894 | [10-K 2026-03-13] |
| 2026-05-05 | 4,510,182 | [10-Q 2026-05-12] |
| 2026-08-04 | 4,552,305 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-01-30; declared effective 2026-02-09 [S-3 2026-01-30]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-10-03. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-10-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-03] |
| 2025-06-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-23] |
| 2025-04-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-10] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-09 | Eade Katherine A. | grant | 16,556 | — | [4 2026-06-12] |
| 2026-06-09 | Snider William | grant | 16,556 | — | [4 2026-06-11] |
| 2026-06-09 | Denelsky Stephen J | grant | 16,556 | — | [4 2026-06-11] |
| 2026-06-09 | Gagnon Robert E. | grant | 16,556 | — | [4 2026-06-11] |
| 2026-06-09 | Benson Seth Benjamin | grant | 16,556 | — | [4 2026-06-11] |
| 2026-03-20 | Frost Mark T | grant | 30,000 | — | [4 2026-04-01] |
| 2026-03-20 | Duke John D | grant | 75,000 | — | [4 2026-03-23] |
| 2026-03-16 | Frost Mark T | buy | 5,000 | $5.00 | [4 2026-04-01] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-22 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Regulation FD disclosure |
| 2026-08-11 | 8-K | Results of operations |
| 2026-06-02 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Regulation FD disclosure |
| 2026-05-12 | 8-K | Results of operations |
| 2026-04-21 | DEF 14A | Proxy statement |
| 2026-03-23 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-03-17 | 8-K | Regulation FD disclosure |
Alerts for $HBIO
Email me when Harvard Bioscience Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.